Calcium homeostasis in cisplatin resistant epithelial ovarian cancer

Bahire Kucukkaya1, Harun Basoglu2, Demet Erdag3, Fahri Akbas4, Seda Susgun4 and Leman Yalcintepe3

1 Department of Biophysics, Faculty of Medicine, Istanbul Yeni Yuzuil University, Istanbul, Turkey
2 Department of Biophysics, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
3 Department of Biophysics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
4 Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey

Abstract. Intracellular calcium concentration ([Ca^{2+}]_i) may have an important role in the development of chemoresistance, which is an essential problem in cancer chemotherapy. Cisplatin (DDP), which modulates the intracellular calcium concentration by different mechanisms, is an antineoplastic agent with high success rate in cancer therapies. We investigated the regulatory role of [Ca^{2+}]_i in cisplatin resistance in epithelial ovarian cancer cell line, in MDAH-2774, and its chemoresistant subclone MDAH-2774/DDP. The measurement of [Ca^{2+}]_i using fluorescence microscope, and flow cytometry revealed that the amount of intracellular calcium decreased in cisplatin resistant cells compared to the amounts in parental cells. mRNA expression profiles of calcium homeostasis-associated major genes (IP3R1/2/3, RYR1/2, SERCA1/2/3, NCX1/2/3, PMCA1/2/3, and PMCA4) decreased in cisplatin resistant cell line in comparison to the expression profiles in parental cells. Owing to the changes in the expression of genes involved in calcium regulation, these results show, drug resistance may be prevented by introducing a new perspective on the use of inhibitors and activators of these genes, and thus of cytostatic treatment strategies, due to changes in the expression of genes involved in calcium regulation.

Key words: Drug resistance — MDAH-2774 — Cisplatin — Calcium

Introduction

Cytotoxic drugs such as doxorubicin, paclitaxel, or cisplatin (cis-diamine-dichloroplatinum (II) or DDP) damage the 'genetic material' of cells by interfering with the proliferation of cancer cells. That might be caused by cell cycle arrest and/or apoptosis (Florea and Büsselberg 2011a, 2011b; Kim et al. 2011; Kutanzi et al. 2011; Galluzzi et al. 2012). Cisplatin induces concentration-dependent cytotoxicity in diverse types of cancer cells due to targeting at the DNA level, in addition with the transcription and replication mechanisms (Shen et al. 2012). Furthermore, cisplatin targets tumor cells due to its feature to trigger 'on' signal transduction pathways (e.g., death receptor, calcium signaling, mitochondrial-dependent apoptosis) that results in tumor cell death (Florea and Büsselberg 2011a, 2011b; Galluzzi et al. 2012).

Ovarian cancer is the most fatal gynecologic malignancy worldwide. Ovarian cancer cell lines can potentially overcome the experimental limitations inherent both in animal models of ovarian cancer, and the primary cloning of human ovarian cancer specimens (Karabulut et al. 2010). Ovarian cancer is a model disease to investigate chemotherapeutic resistance owing to its intrinsic, and acquired resistance to drugs. Cisplatin is the first globally approved platinum drug which has been used in cancer chemotherapy for more than 30 years(Achkar et al. 2018). Significant challenges regarding cisplatin resistance, and cisplatin-induced toxicity still remain despite the widely use of cisplatin as an anticancer drug. Cisplatin resistance is mostly a secondary effect, and its mechanism is unclear. Cisplatin resistance may be associated with the altered regulation of multiple signaling pathways, including downregulation of apoptotic signals, and activation of pro-survival signals (Ali et al. 2012; Gal-
Materials and Methods

Cell line and chemicals

Human epithelial ovarian cancer (EOC) cell line, MDAH cells were obtained from the Department of Biophysics in Istanbul Faculty of Medicine, and maintained in Dulbecco's Modified Eagles medium (DMEM) F-12 supplemented with 10% heat-inactivated fetal calf serum (FCS), and 100 IU/ml penicillin–streptomycin. Incubation conditions at 37°C in a humidified atmosphere of 5% CO2 were maintained in a Heraeus incubator (Hanau, Germany). Cisplatin (Sigma) was applied to the MDAH cell line with dose increments. The subline resistant to cisplatin (MDAH/DDP) from parental MDAH cell line was developed by increasing the 5 μM dose, stepwise, 5 μM to 70 μM for cisplatin. Before the dose increments, adapted cells became confluent in respective drug concentrations and maintained at least for three weeks (approximately 3–4 weeks). Cells selected in 25 μM cisplatin were maintained in medium with 25 μM cisplatin for assays.

3-(4,5)-dimethyl thiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) assay, cell viability assay

Cell viability was assessed using the MTT cell staining as previously described (Previcpe et al. 2009). MDAH and MDAH/DDP groups were seeded in 96-well plates in triplicate at a density of 2×10^4 cells per well, and cultured for 24 hours in DMEM containing 10% FCS. MDAH/DDP group was treated using various concentrations of cisplatin (0 to 70 μM) for 24 hours at 37°C. After drug exposure, we added MTT working solution into wells being assayed at 37°C for 30 min to 4 hours. We removed medium with a needle, added 100 μl of DMSO to each well, and pipetted up and down to dissolve crystals. Absorbance of the converted dye was measured at a wavelength of 570 nm by microplate ELISA reader. Data were presented as the percentage cell viability calculated using the following formula: Cell viability (%) = (sample OD/control OD) × 100.

RNA isolation and Real-Time Quantitative RT-PCR

For the isolation of the total RNA, MDAH and MDAH/DDP cells were cultured in four wells for each treatment, and the total RNA was extracted using total RNA extraction kit (Thermo). The concentration of the extracted RNA was determined by spectrophotometric analysis (MultiSkans Go, Thermo). Purified RNA (500 ng) was used for cDNA synthesis using RevertAid First Strand cDNA synthesis kit (Thermo Scientific) in accordance with the manufacturer's instructions. Reverse transcription polymerase chain reaction (RT-PCR) was performed using primers specific for IP3R1 (Bacillus subtilis), RYR1 (Bacillus subtilis), SERCA1a (Bacillus subtilis), NCX1 (Bacillus subtilis), and PMCA1 (Bacillus subtilis) genes (Table 1). Specific PCR primers were designed using primer3 software (http://primer3plus.com/). The primer sequences of the genes are given in Table 1. Quantitative analysis was performed using the Fast SYBR Green Master Mix (Thermo). Reaction mixture contained a total volume of 20 μl. The PCR conditions were 95°C for 3 minutes, then 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. The relative amount of target mRNA in test sample was calculated, and normalized to the corresponding β-actin
Cells were seeded in 6 well plates on glass cover slips at a density of 2×10^4 for 24 hours. After washing with PBS, they were then loaded with 0.5 ml of 5 μM Furo-2AM, dissolved in HBSS from stock solution of 1.5 mM in DMSO containing 20% pluronic acid F-127 at room temperature for 30 min, and subsequently rinsed twice with HBSS. Cells were then analyzed using a Zeiss axio observer Z1 inverted fluorescence microscope (Germany). The fluorescence intensity was calculated as Grynkiewicz's equation (Grynkiewicz et al. 1985).

Western blotting

MDAH, and MDAH/DDP cells were harvested, and cells in equal numbers were analyzed using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; acrylamide, Sigma-Aldrich; bisacrylamide, Amresco, Solon, OH, USA; Tris, Sigma-Aldrich; TEMED, Sigma-Aldrich; ammonium persulfate, Sigma-Aldrich), as previously described (Laemmli 1970). Briefly, equal numbers(2×10^5 cells) of cell lysate were loaded onto SDS-PAGE gels using the Mini-PROTEAN Electrophoresis System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Prestained molecular weight standards (Precision Plus Protein Standards, Bio Rad) were used for size estimation. Proteins were transferred electrophoretically onto nitro-cellulose membranes (Towbin et al. 1970). The membranes were blocked with Tris-Buffered Saline (TBS) containing 3% bovine serum albumin (BSA), and 0.05% Tween-20 at room temperature and incubated overnight at 4°C with the relevant primary antibody. Anti-Bcl-2 monoclonal antibody(used at 1:100 dilution, catalog number, ABM40029) were obtained from Abbkine. Primary antibodies were detected by incubation with secondary alkaline phosphatase-conjugated anti-mouse antibody for 1 h at room temperature (dilution; 1:1000), followed by 3 washes with TBST. Alkaline phosphatase activity was detected using 5-bromo-4-chloro-3′-indolyl phosphate/nitro-blue tetrazolium as substrate (Promega Corp., Madison, WI, USA) for colorimetric detection.

Flow cytometry analysis

To determine [Ca^{2+}]_i, 2×10^4 cells were rinsed with HBSS (20 mM Hepes, 10 mM glucose, 150 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1 mM Na₂HPO₄, pH 7.4). They were then loaded with 0.5 ml of 5 μM Furo-2AM, dissolved in HBSS from stock solution of 1.5 mM in DMSO containing 20% pluronic acid F-127 at room temperature for 30 min, and subsequently rinsed twice with HBSS. Cells were then analyzed using a BD Aria flow cytometer (BD Bioscience, San Jose, CA, USA).

Table 1. The primer sequences of the genes

| General Name | Primer Pairs (5'-3') | Product Size (bp) |
|--------------|----------------------|------------------|
| IP₃R1        | Forward: TGACGAGAACCTGCCTAT Reverse: TCTCTTTCGCCATCTTGGT | 304 |
| IP₃R2        | Forward: GCAATCGTGTCTGTCCCA Reverse: TCTCTAAGITCTCAGCATCG | 332 |
| IP₃R3        | Forward: GCCTAATGAGAACCCACAGG Reverse: TCAAGGAAGCAATGAGATGAG | 389 |
| RYR1         | Forward: TGACTCCATCGAGGCAGAA Reverse: ACGAAGACGCGAGAAATA | 297 |
| RYR2         | Forward: AACAGTTACATGGCTGGTTG Reverse: TTGTCTCTACAGGGAACAGGG | 348 |
| SERCA1       | Forward: GTGATGGGCTTCGCTATG Reverse: CGAAAAAGGTCCGGTCT | 361 |
| SERCA2       | Forward: GCTGACTCTACTGCTGCA Reverse: TCGGGTATAGGGGATACAA | 406 |
| SERCA3       | Forward: GAGAGGTAGAAGCCAGCA Reverse: TCAAGGGAAGGAGAAGAAA | 409 |
| NCX1         | Forward: GTGGACATGGAGAAATCA Reverse: CCAGGGAAGGAGAAGAAA | 373 |
| NCX2         | Forward: CGGTGAGAATACGTACAAAG Reverse: CAGGGCAAGGAGGAGGAACA | 359 |
| NCX3         | Forward: GAGATGGGGAAGGCCAGAT Reverse: ATGGGAAAACAAAACAGG | 430 |
| PMCA1        | Forward: GAGATGGGGAAGGCCAGAT Reverse: ATGGGAAAACAAAACAGG | 418 |
| PMCA2        | Forward: GAGATGGGGAAGGCCAGAT Reverse: ATGGGAAAACAAAACAGG | 214 |
| PMCA3        | Forward: TTGGTCCTCTACTTCTTGTGATTTG Reverse: TGGTGTTATAGCCAGTG | 417 |
| PMCA4        | Forward: CTGGTGCATGAGAATGTCG Reverse: AGTCCGCGGTAACGCTATG | 279 |

mRNA transcript level as a housekeeping gene. All reactions were performed three times, and the mean values were used. Transcriptional gene expression, which is subsequently referred to as gene expression, was defined as fold change (FC) versus ethanol-treated controls and it was determined with the ΔΔCt method (Schmittgen and Livak 2008).

Statistical analysis

Data were expressed as mean ± standard error of the mean (SEM). The non-parametric Kruskal-Wallis test was applied followed by Dunn'spost-test for multiple comparisons to test the significance of the various data collected during the study. Statistical comparisons of fluorescence microscopy images were performed utilizing a two-tail Welch's corrected t-test for parametric data or a two-tail Mann-Whitney test for non-parametric data.

Confocal fluorescence microscope analysis

Western blots were probed with antibodies directed against Bcl-2, GAPDH, and β-actin were probed with antibodies directed against GAPDH, and β-actin. The membranes were then washed with PBS and incubated with donkey anti-rabbit or anti-mouse secondary antibodies conjugated to horseradish peroxidase. Immunoreactive bands were visualized using an enhanced chemiluminescence detection system.
Results

Growth inhibition of cisplatin resistant cells

Drug resistant subclone MDAH/DDP established by step-wise treatment with increasing cisplatin concentration, is resistant to up to 24 µM cisplatin. The effect of anti-cancer drug cisplatin on MDAH cell line viability was determined using MTT colorimetric assay. The MDAH and MDAH/DDP cells were treated with cisplatin for 24 hours (Fig. 1). Cisplatin decreased cell viability both in MDAH and MDAH/DDP cells in time and dose-dependent manner. As shown in Figure 1, IC50 value of MDAH cells was 8.6 µM and IC50 value of MDAH/DDP cells was 47.64 µM. A 5.5-fold difference in IC50 value was found between the cell lines (p < 0.01, n = 3).

Expression levels of Ca\(^{2+}\)-related genes

To assess the effects of cisplatin resistance on mRNA expression, relative gene expression differences of fifteen selected genes (IP\(_3\)R 1/2/3, RYR 1/2, SERCA 1/2/3, NCX 1/2/3, PMCA 1/2/3/4) between MDAH and MDAH/DDP were examined by quantitative RT-PCR (Fig. 2). Comparison of the 2\(^{−ΔΔCt}\) values were performed by the measurement of the MDAH and MDAH/DDP cells. A two-fold expression difference (p < 0.05) was taken as a cut-off level.

We tested the gene expression of endo/sarcoplasmic reticulum calcium channels, IP\(_3\)Rs and RYRs. We showed that IP\(_3\)R2 expression level of MDAH/DDP cells significantly decreased (103-fold) and also observed a decrease in the expression of IP\(_3\)R1 and IP\(_3\)R3 gene. An increase was observed in the comparison of RYR1 expression in MDAH/DDP with RYR1 expression in MDAH cells, while RYR2 of gene expression significantly decreased in cisplatin resistant cells.

We investigated whether there was a change in the expression of SERCA1/2/3, which is responsible for the regulation of cytoplasmic Ca\(^{2+}\), in cisplatin resistant MDAH cells and MDAH cells. We found that SERCA1/2/3 expressions levels in MDAH/DDP cells were lower than MDAH cell in the comparison of the SERCA1/2/3 mRNA expression levels in MDAH and the MDAH/DDP cells. We then examined gene expressions of Na\(^+\)/Ca\(^{2+}\) exchanger 1/2/3 (NCX) genes. We found an increase in NCX3 although a decrease in mRNA expression of NCX1 and NCX2 was detected in cisplatin resistant cells. In addition, we examined the plasma membrane Ca\(^{2+}\)-ATPase (PMCA), which is a transport protein in the plasma membrane of cells and which functions to remove Ca\(^{2+}\) from the cell. A slight decrease was detected in PMCA2/3, and 4 expressions in the comparison of MDAH/DDP cells with MDAH cells. PMCA1 expression level in MDAH/DDP was higher than the expression level in MDAH cells.

Flow cytometry

Measurement of cytosolic calcium levels in MDAH, and cisplatin resistant MDAH cells were detected by Fura-2-acetoxyethyl ester staining, and flow cytometry. Histograms Fig. 3A and 3B, and bar graph in Fig. 3C showed that MDAH cells had a significantly higher concentration of calcium ions in the cytosol than MDAH/DDP cells.

Fluorescence microscope analysis

MDAH, and cisplatin resistant MDAH cells were treated with 5 µM Fura-2 for 30 min, and the intracellular Ca\(^{2+}\) changes were detected by fluorescence microscopy. The intracellular Ca\(^{2+}\) concentration was expressed as the 340/380 ratio (MDAH; n = 16, cisplatin resistance MDAH/DDP; n = 10). Inverted fluorescence microscopy images revealed that MDAH

![Figure 1. Dose response of cisplatin after 24 hours treatment in MDAH cell line. Cell viability was measured using MTT assay as described in Methods section. The values represent the mean cell survival ± standard deviation (SD) from three independent experiments compared with the untreated control cells (100% survival).](image)
cells treated with cisplatin for 24 h showed a significant decrease in green fluorescence (Fig. 4A2). Also, quantification of the area and the total intensity fluorescence of intracellular calcium in cisplatin resistant MDAH cells were decreased when compared with the values in MDAH cells (Fig. 4B and C). These findings showed that cisplatin appears to induce decrease in Ca$^{2+}$ concentrations in the cytosol in MDAH cells.

**Western blotting**

We examined the expression of Bcl-2 (26 kDa), an anti-apoptotic protein, to demonstrate apoptosis in cells treated with cisplatin, and in the cells not treated with cisplatin (Fig. 5). We showed that Bcl-2 protein expression was lost in cisplatin-resistant cells.

**Discussion**

Ovarian cancer is a common cancer of the female reproductive organs, and is associated with the highest death rates among all gynecological cancers (Chen et al. 2013). Cisplatin chemotherapy, and adjuvant therapy are common in ovarian cancer and drug resistance is a major cause of death (Book-Gurry et al. 2009). The effects of cisplatin on calcium homeostasis in MDAH cells are observed in the decrease in calcium ions in the cytosol, as measured by flow cytometry.

**Figure 2.** Gene expression of Ca$^{2+}$ channels, pumps, and exchangers in MDAH and MDAH/DDP. mRNA expression profiles of major genes; IP$_3$R1/2/3, RYR1/2, SERCA1/2/3, NCX1/2/3, and PMCA1/2/3/4 associated to calcium homeostasis in MDAH/Control and MDAH/DDP cells were examined by quantitative RT-PCR. Expression levels were adjusted to β-actin for each sample and graphed as fold-changes relative to MDAH cells.

**Figure 3.** Measurement of cytosolic calcium levels in MDAH/Control and MDAH/DDP cells by Fura-2-acetoxymethyl ester staining and flow cytometry. Histograms (A) and (B), and bar graph (C) showing that MDAH cells had a significantly higher concentration of calcium ions in the cytosol than MDAH/DDP cells. $p < 0.05$ compared to MDAH/Control cells.
Identifying the resistance mechanism is therefore very important. Mostly, cisplatin resistance is a secondary effect, and its mechanisms are unclear. Cisplatin resistance may be associated with the altered regulation of multiple signaling pathways, including downregulation of apoptotic signals, and activation of pro-survival signals (Ali et al. 2012; Galluzzi et al. 2012; Davis et al. 2014). Recent studies have shown that the calcium signal is implicated in a variety of important processes in tumor progression (e.g. proliferation and invasiveness). Calcium signal was also shown to be important in other processes in cancer progression including the development of resistance to current cancer therapies (Xu et al. 2015b). Therefore, we hypothesized that cancer drug resistance alters intracellular Ca\(^{2+}\) signaling through an IP\(_3\)R, RyR, SERCAs, NCXs and PMCAs controlled pathway. We used MDAH cells and MDAH/DDP cells as an in vitro model of cisplatin resistance. We selected cisplatin for testing because cisplatin induces cytoplasmic Ca\(^{2+}\) elevation by an IP\(_3\)-dependent mechanism (Splettstoesser et al. 2007). We first showed the dose response in MDAH and MDAH/DDP cells after 24 h with cisplatin treatment. Our cytotoxicity studies revealed that MDAH/DDP cells were resistant to cisplatin-induced apoptosis, the IC50 of cisplatin was 5.5 times higher in these cells compared to their parent cell line.

In the present study, we demonstrated that cisplatin resistance has the ability to modulate calcium homeostasis in MDAH cells. In fluorescence microscopy images, cytosolic Ca\(^{2+}\) was reduced in MDAH/DDP cells compared to levels in MDAH cells. Fluorescence microscopy results were confirmed by flow cytometer analysis. Cytosolic calcium levels were shown to decrease in cisplatin resistant cells compared with MDAH cells by flow cytometry. This finding emphasized that calcium signaling might play a major role in acquired drug resistance and failure in triggering apoptosis by cisplatin.

Various studies have described changes in different cancer cell types and models in intracellular Ca\(^{2+}\) signals induced by some anti-cancer agents. Drug treatments that appeared to increase Ca\(^{2+}\) influx as a result of short-term (0 to 8 h) exposure included 5-Fluorouracil (5FU) (Can et al. 2013), dexamethasone (Abdul-Azize et al. 2017), Tipifarnib (Cuevas 2011; Yanamandra et al. 2011) or ionizing radiation (Klumpp et al. 2016). Drugs such as arsenic trioxide (As\(_2\)O\(_3\)) (Gunes et al. 2009) and gamitrinib (Park et al. 2014) were suggested to promote ER Ca\(^{2+}\) release during short-term exposure. Short-term exposure of cancer cells to cisplatin (Shen et al. 2016; Chakraborthy et al. 2017), doxorubicin (Giorghi et al. 2015a), or photodynamic therapy (PDT) (Giorghi et al. 2015b), may enhance ER-mitochondria Ca\(^{2+}\) transfer in some models. Examples of the remodeling of Ca\(^{2+}\) signaling with longer term drug treatments include altered store-operated Ca\(^{2+}\) entry (SOCE) as a result of treatment with 5-Fluorouracil (Kondratska et al. 2014; Tang et al. 2017), gemcitabine (Kondratska et al. 2014) or cisplatin (Schmidt et al. 2014). Long-term treatment with vemurafenib (Hegedus et al. 2017) can enhance cytosolic Ca\(^{2+}\) removal after store-operated Ca\(^{2+}\) entry. Altered ER calcium release mediated by SERCA inhibition is observed in cisplatin-resistant cancer cells (generated from prolonged exposure of cancer cells to cisplatin), i.e. reduced in resistant lung cancer cell lines(Schrodl et al. 2009), and increased in resistant ovarian cancer cell lines (Schmidt et al. 2014). Our

![Figure 4](image_url)

**Figure 4.** Representative fluorescence intensity and the area variations between MDAH/Control and MDAH/DDP cells. A. Fluorescence microscopy images of MDAH/Control (a) and MDAH/DDP (b) cells stained by Fura-2. B. Quantification of the area of MDAH/Control and MDAH/DDP cells. The mean area value of MDAH cells was 741.3218 ± 292.7147 and the area of the cisplatin resistant cells was 595.8555 ± 248.1282. Data are mean ± SD. Statistical comparisons were performed utilizing unpaired t-test with Welch correction for parametric data by Graphpad Prism and p > 0.05. C. Quantification of the total intensity fluorescence of intracellular calcium. Data are expressed as mean calcium fluorescence intensity ± SD. Statistical comparisons were performed utilizing unpaired t-test Welch corrected for parametric data; p < 0.0001 compared to MDAH/Control cells.
results confirm that the overall effect of drug treatment is to alter the \([\text{Ca}^{2+}]\), effect that is likely to be linked to its ability to trigger apoptosis (Muscella et al. 2011).

The intracellular \(\text{Ca}^{2+}\) homeostasis is governed by a network composed of various \(\text{Ca}^{2+}\) channels, pumps, and exchangers. Intracellular \(\text{Ca}^{2+}\) alterations may be generated by an interaction of the drugs with \(\text{IP}_3\) receptors, ryanodine receptors, NCX exchangers, SERCA and PMCA pumps resulting in a depletion of intracellular calcium stores. Therefore, we investigated and compared the possible presence of aberrations in multiple \(\text{Ca}^{2+}\) channels, pumps, and exchangers in MDAH and MDAH/DDP cells. The \(\text{IP}_3\)Rs are a ubiquitous family of \(\text{Ca}^{2+}\) release channels composed of three isoforms (1, 2 and 3) which present primarily in the ER. \(\text{IP}_3\), produced by phospholipase C after cell activation by hormones, growth factors or neurotransmitters, diffuses into the cytosol, binds to and activates the \(\text{IP}_3\)R leading to \(\text{Ca}^{2+}\) release from the endoplasmic reticulum. ER, a major intracellular \(\text{Ca}^{2+}\) storage organelle, is involved in several biological processes (Foskett et al. 2007). Altered \(\text{IP}_3\)R expression level profiles were found in colon, glioma, gastric, head and neck cancer (Sakakura et al. 2003; Kang et al. 2010; Shibao et al. 2010; Hedberg et al. 2016). Over the last 20 years, \(\text{IP}_3\)R channels have emerged as key regulators that control cell death and survival in a variety of cellular systems (Joseph et al. 2007; Decuyper et al. 2011; Ivanova et al. 2014). Also, the role of \(\text{IP}_3\)R2 in cell death has been elucidated in different studies using different approaches. \(\text{IP}_3\)R2 channels are not only implicated in apoptosis but also play a role in cellular senescence (Vervloessem et al. 2015). There is evidence that cell death triggered by cellular exposure to cytotoxic compounds and agents that induce oxidative stress were associated with an increase in \(\text{IP}_3\)R2 levels, and activity. Increasing oxidative stress in a neuronal cell line exposed to sublethal concentrations of tert-butyl hydroperoxide-mediated oxidative stress led to prominent upregulation of \(\text{IP}_3\)R2 mRNA and protein levels, while \(\text{IP}_3\)R1 and \(\text{IP}_3\)R3-expression levels remained unaltered (Kaja et al. 2011). Carboplatin (CARB) treatment can increase the activity of \(\text{Ryr} \text{Ca}^{2+}\) release channels on the ER via GSTO1 (Lu et al. 2017). In our study, \(\text{IP}_3\)R1, and \(\text{IP}_3\)R3 gene expression levels were relatively decreased in MDAH/DDP cells compared to MDAH cells, but \(\text{IP}_3\)R2 gene expression level is decreased significantly in MDAH/DDP cells. This can mean two things: i) \(\text{IP}_3\)R2, similar to other \(\text{IP}_3\)R isoforms, is regulated in a biphasic way by the cytosolic \([\text{Ca}^{2+}]\), meaning that a relatively low \([\text{Ca}^{2+}]\) potentiates \(\text{IP}_3\)-induced \(\text{Ca}^{2+}\) release, while higher \([\text{Ca}^{2+}]\) leads to an inhibition of the \(\text{IP}_3\)R2 (Vervloessem et al. 2015) and, ii) dampening the \(\text{IP}_3\)R3-mediated \([\text{Ca}^{2+}]\), either by lowering \(\text{IP}_3\)R levels or altering the \(\text{IP}_3\)R-expression profile, by inhibiting the \(\text{Ca}^{2+}\)-flux properties of \(\text{IP}_3\)R3s, or by lowering the ER \(\text{Ca}^{2+}\) content, which decreases the driving force for \(\text{Ca}^{2+}\) release into the cytosol upon \(\text{IP}_3\)R activation, will be cytoprotective (Akl and Bultynck 2013a).

Furthermore, it is important to emphasize that a complex interaction exists between \(\text{IP}_3\)R3s, and proteins from the B-cell lymphoma (Bcl-2) family involved in the control of apoptosis, whereby several interaction sites for such proteins have already been identified on the \(\text{IP}_3\)R (Distelhorst and Bootman 2011). Bcl-2 was shown to interact with \(\text{IP}_3\)R, and that this interaction involves binding of the BH4 domain of Bcl-2 to a region located within the regulatory and coupling domain of the \(\text{IP}_3\)R (Rong et al. 2009a). Bcl-2 may also regulate ER \(\text{Ca}^{2+}\) release through other mechanisms in addition to its interaction with \(\text{IP}_3\)R. One proposed mechanism involves Bcl-2 interaction with SERCA. These proteins pump \(\text{Ca}^{2+}\) ions from cytoplasm into the ER lumen, maintaining large ER luminal \(\text{Ca}^{2+}\) stores. This steep \(\text{Ca}^{2+}\) concentration gradient from ER lumen to cytoplasm facilitates \(\text{Ca}^{2+}\) efflux from the ER lumen \(\text{via} \text{IP}_3\)R channel opening, leading to cytoplasmic \(\text{Ca}^{2+}\) elevation. The interaction of Bcl-2 with SERCA attenuates ER \(\text{Ca}^{2+}\) filling, indirectly diminishing \(\text{IP}_3\)R-mediated \(\text{Ca}^{2+}\) release and \(\text{Ca}^{2+}\)-mediated apoptosis (Volpe et al. 1990; Dremina et al. 2004). We found that \(\text{SERCA}1/2/3\) gene expression levels considerably decreased in MDAH/DDP cells. Mutations, and altered expression levels of \(\text{SERCA}\) isoforms were determined in many cancers, including colon, prostate, and in lung cancers. To give an example, \(\text{SERCA}3\) expression was induced in colon adenocarcinoma cell lines during differentiation, and was reported to be lost during multistage process of colon tumorigenesis.
(Brouland et al. 2005). Our results suggested that the down regulation of SERCA might be one of the reason of the decrease in intracellular calcium concentration.

The primary function of Bcl-2 is to inhibit apoptosis. Morphological and biochemical studies demonstrated that Bcl-2 has two major intracellular localizations as mitochondria, and the ER (Hockenbery et al. 1990; Monaghan et al. 1992; Jacobson et al. 1993; Krajewski et al. 1993). An increase in Bcl-2 was suggested to cause resistance to chemotherapeutic agents, and the down-regulation of Bcl-2 enhanced chemosensitivity (Reed et al. 1998). The other result was contradictory because the decrease of Bcl-2 protein expression was also shown in cisplatin resistance in SCLC H69 cells (Kumar Biswas et al. 2004). Bcl-2 was shown to constitutively be phosphorylated at Ser70 in H69 cells but not in H69/DDP cells. They suggested that a decrease in constitutively phosphorylated Bcl-2 in H69/CP cells appeared to be associated with cisplatin resistance (Kumar Biswas et al. 2004), and also with the phosphorylation of Bcl-2 regulated ER Ca²⁺ homeostasis (Bassik 2004). The other article consistent with the previous report suggested that primary SCLC patients with Bcl-2-positive tumors had a complete remission rate of 40% versus 27% complete remissions in patients with Bcl-2-negative tumors after initial chemotherapy (Kaiser et al. 1996). We found that the band of Bcl-2 protein expression disappeared on blotting membrane. These results suggest that the decrease in Bcl-2 protein expression may be due to the rearrangement of calcium homeostasis in resistant cells and due to the resistance to cisplatin-induced apoptosis.

IP₃Rs located at the ER membrane play an essential role in ER to mitochondria Ca²⁺ trafficking, and Bcl-2 could also regulate calcium homeostasis at the ER. Taking all the results together, the first is the reduction of IP₃R expression levels, especially IP₃R2 gene expression level, may inhibit (or suppress) the transfer of Ca²⁺ from the ER to the mitochondria, which increases the apoptotic resistance of cells and may decrease the cellular responsiveness to apoptotic signaling in response to cellular damage or alterations (Akl et al. 2013a); the second is Bcl-2 inhibits IP₃-induced Ca²⁺ release by interacting via its BH4 domain of Bcl-2 with the modulatory and transducing domain of the IP₃Rα (Chen et al. 2004; Rong et al. 2008, 2009). The binding site for the BH4 domain of Bcl-2 has been identified (Rong et al. 2008), and is conserved between the three IP₃R isoforms (Monaco et al. 2012). Importantly, a peptide tool designed to disrupt IP₃R/Bcl-2-complexes by targeting Bcl-2’s BH4 domain (Rong et al. 2008, 2009a, 2009b; Monaco et al. 2012) was very effective in inducing intracellular Ca²⁺ overload, and in provoking cell death in DL-BCL cells that express high levels of IP₃R2, such as SU-DHL-4 cells (Akl et al. 2013b). Therefore, our results suggested that the interaction of Bcl-2, and IP₃R2 on ER may inhibit Ca²⁺ transfer from ER to cytosol, protect the rise in Ca²⁺ increase in cytosolic, and prevents apoptosis.

PMCA is an important calcium transporter in all cells, and plays an essential role in maintaining low intracellular Ca²⁺ levels through the active transport of calcium across the plasma membrane. We showed that PMCA1 expression levels increased, and PMCA2/3/4 expression level decreased compared to parental MDAH cells. Furthermore, we found that Na⁺/Ca²⁺ exchanger expression profiles differ between cisplatin resistant and parental cells. NCX1 and NCX2 expression levels were lower in MDAH/DDP cells. NCX3 expression level was higher in resistant cells and this result was consistent with the result in the study of Pelzl et al. (2015).

In the light of these data, the induction of RyRs, IP₃Rs and SERCAs receptor and pumps on ER and NCX and PMCA channels on cell membrane, and also Bcl-2 protein expression were a result of cisplatin resistance, and cisplatin resistance must be further investigated.

**Conclusion**

Ca²⁺ signaling seems to play an important role from cancer initiations to drug resistance. It becomes evident that drug resistance is associated with major changes in the expression of specific Ca²⁺ channels/transporters/pumps. It is important to identify the dysregulated Ca²⁺ channels/transporters/pumps that contribute to chemoresistance, which may provide a promising chemotherapy for cancer patients. Therefore, evaluation of the blockers, inhibitors or regulators for Ca²⁺ channels/transporters/pumps as anti-cancer drugs seem to provide promising leads for novel cancer treatment in the future years.

**Acknowledgement.** This study was funded by Scientific Research Projects Coordination Unit of Istanbul University. Project number: TSA-2017-24579.

**Conflict of interest.** There was no conflict of interest.

**References**

Abdoul-Azize S, Dubus I, Vannier JP (2017): Improvement of dexamethasone sensitivity by chelation of intracellular Ca2+ in pediatric acute lymphoblastic leukemia cells through the prosurvival kinase ERK1/2 deactivation. Oncotarget 8, 27339-27352 [https://doi.org/10.18632/oncotarget.16039](https://doi.org/10.18632/oncotarget.16039)

Achkar IW, Abdulrahman N, Al-Sulaiti H, Joseph JM, Uddin S, Mraiche F (2018): Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J. Transl. Med. 16, 1-12 [https://doi.org/10.1186/s12967-018-1471-1](https://doi.org/10.1186/s12967-018-1471-1)

Akl H, Baltynck G (2013a): Altered Ca2+ signaling in cancer cells: proto-oncogenes and tumor suppressors targeting IP3 receptors. Biochim. Biophys. Acta 1835, 180-193
Akl H, Monaco G, La Rovere R, Welkenhuyzen K, Kiviluoto S, Vervliet T, Molgó J, Distelhorst CW, Missiaen L, Mikoshiba K, et al. (2013b): IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2. Cell Death Dis. 16, e632 https://doi.org/10.1038/cddis.2013.140

Ali AY, Byun S, Farrand L, Kim JY, Lee HJ, Lee HJ, Suh JY, Tsang BK (2012): Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann. N. Y. Acad. Sci. 1271, 58-67 https://doi.org/10.1111/j.1749-6632.2012.06734.x

Bassik MC, Scorrano L, Oakes S, A, Pozzan T, Korsmeyer SJ (2004): Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J. 23, 1207-1216 https://doi.org/10.1038/sj.emboj.7600104

Bookman MA (2012): First-line chemotherapy in epithelial ovarian cancer. Clin. Obstet. Gynecol. 55, 96-113 https://doi.org/10.1097/GCO.0b013e3182e1824b5da

Brouland JP, Gelebart P, Kovacs T, Enouf J, Grossmann J, Papp B (2005): The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am. J. Pathol. 167, 233-242 https://doi.org/10.1016/S0002-9440(10)62968-9

Can G, Akpınar B, Baran Y, Zhivotovsky B, Olsson M (2013): 5-Fluorouracil signaling through a calcium-calmodulin dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene 32, 4529-4538 https://doi.org/10.1038/onc.2012.467

Chakraborty PK, Mustaﬁ SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, et al. (2017): MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat. Commun. 8, 14634 https://doi.org/10.1038/s41467-017-0037

Chen H, Fang F, Liu GJ, Xie HY, Zou J, Feng D (2013): Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst. Rev. 6, CD007414 https://doi.org/10.1002/14651858.CD007414.pub3

Chen R, Valencia I, Zhong F, McColl KS, Roderick HL, Bootman MD, Berridge MJ, Conway SJ, Holmes AB, Mignery GA, et al. (2004): Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J. Cell Biol. 19, 193-203 https://doi.org/10.1083/jcb.20030914

Cuevas J (2011): Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J. Pharmacol. Exp. Ther. 337, 636-643 https://doi.org/10.1124/jpet.110.172809

Davis A, Tinker AV, Friedlander M (2014): “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol. Oncol. 133, 624-631 https://doi.org/10.1016/j.ygyno.2014.02.038

Decuypere JP, Monaco G, Bulyntyk G, Missiaen L, De Smedt H, Parys JB (2011): The IP (3) receptor-mitochondria connection in apoptosis and autophagy. Biochim. Biophys. Acta 1813, 1003-1013 https://doi.org/10.1016/j.bbamcr.2010.11.023

Distelhorst CW, Bootman MD (2011): Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: role in Ca2+ signaling and disease. Cell Calcium 50, 234-241 https://doi.org/10.1016/j.ceca.2011.05.011

Dremina ES, Sharov VS, Kumar K, Zaidi A, Michaelis EK, Schöneich C (2004): Anti-apoptotic protein Bcl-2 interacts with and destabilizes the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA). Biochem. J. 383, 361-370 https://doi.org/10.1042/BJ20040187

Florea AM, Büsselberg D (2006): Occurrence, use and potential toxic effects of metals and metal compounds. Biometals 19, 419-427 https://doi.org/10.1007/s10534-005-4451-x

Florea AM, Büsselberg D (2009): Anti-cancer drugs interfere with intracellular calcium signaling. Neurotoxicology 30, 803-810 https://doi.org/10.1016/j.nurotox.2009.04.014

Florea AM, Büsselberg D (2011a): Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 15, 1351-1371 https://doi.org/10.3390/cancers1501351

Florea AM, Büsselberg D (2011b): Metals and breast cancer: risk factors or healing agents?. J. Toxicol. 2011, 1-8 https://doi.org/10.1155/2011/159619

Foskett JK, White C, Cheung K-H, Mak D-O (2007): Inositol trisphosphate receptor Ca2+-release channels. Physiol. Rev. 87, 593-658 https://doi.org/10.1152/physrev.00035.2006

Galluzzi L, Senovilla L, Vitale I, Michels I, Kepp O, Castedo M, Kroemer G (2012): Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 https://doi.org/10.1038/onc.2011.384

Giorgi C, Bonora M, Missirolli S, Poletti F, Ramirez FG, Morciano G, Morganti C, Pandolfi PP, Mammano F, Pinton P (2015a): Intravital imaging reveals p53 dependent cancer cell death induced by phototherapy via calcium signaling. Oncotarget 6, 1435-1445 https://doi.org/10.18632/oncotarget.2935

Giorgi C, Bonora M, Sorrentino G, Missirolli S, Poletti F, Suski JM, Ramirez FG, Rizzuto R, Di Virgilio F, Zito E, et al. (2015b): p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner. Proc. Natl. Acad. Sci. USA 112, 1779-1784 https://doi.org/10.1073/pnas.1410723112

Grynkwicz G, Poenie M, Tsien RY (1985): A new generation of Ca(2+) indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450

Gunes DA, Florea AM, Spletstoesser F, Büsselberg D (2009): Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on intracellular calcium signaling. Oncotarget 14, 3440-3450 https://doi.org/10.18632/oncotarget.2935

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freiilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, et al. (2016): Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J. Clin. Invest. 126, 169-180
Hegeduš L, Garay T, Molnar E, Varga K, Bilecz A, Torok S, Padanyi R, Paszty K, Wolf M, Grusch M, et al. (2017): The plasma membrane Ca(2+) pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells. Int. J. Cancer 140, 2758-2770. https://doi.org/10.1002/ijc.30503

Hockenberg D, Nuñez G, Milliman C, Schreider RD, Korsmeyer SJ (1990): Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334-336. https://doi.org/10.1038/348334a0

Ivanova H, Vervliet T, Missiaen L, Parys JB, De Smedt H, Bultynck G (2014): Inositol 1,4,5-trisphosphate receptor-isof orm diversity in cell death and survival. Biochim. Biophys. Acta 1843, 2164-2183. https://doi.org/10.1016/j.bbamcr.2014.03.007

Jacobson MD, Jurine JK, King MP, Miyashita T, Reed JC, Raff MC (1993): Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature (London) 361, 365-369.

Joseph SK, Hajnóczky G (2007): IP3 receptors in cell survival and apoptosis: Ca2+ release and beyond. Apoptosis 12, 951-968. https://doi.org/10.1007/s10495-007-0719-7

Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, Havemann K (1996): Expression of bcl-2 protein in small cell lung cancer. Lung Cancer 15, 31-40. https://doi.org/10.1016/0169-5002(96)00568-5

Kaja S, Duncan RS, Longoria LD, Payne AJ, Desai NM, Parikh RA, Burroughs SL, Gregg EV, Goad DL, Koulen P (2011): Novel mechanism of increased Ca2+ release following oxidative stress in neuronal cells involves type 2 inositol-1,4,5-trisphosphate receptors. Neuroscience 175, 281-291. https://doi.org/10.1016/j.neuroscience.2010.11.010

Kang SS, Han KS, Ku BM, Lee YK, Hong J, Shin HY, Almonte AG, Wolf MR, Brat DJ, Hwang EM, et al. (2010): Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res. 70, 1173-1183. https://doi.org/10.1158/0008-5472.CAN-09-2886

Karabulut B, Karaca B, Varol U, Muslu U, Calkar B, Atmaca H, Kisim A, Uznugolu S, Uslu R (2010): Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. J. Exp. Clin. Cancer Res. 30, 10. https://doi.org/10.1186/1756-9966-29-102

Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, Green JE (2011): A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One 6, 16694. https://doi.org/10.1371/journal.pone.0016694

Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP (2011): MicroRNA-mediated drug resistance in breast cancer. Clin. Epigenetics 2, 171-185. https://doi.org/10.1186/s13148-011-0040-8

Klumpp D, Misovic M, Szteyn K, Shumilina E, Rudner J, Huber SM (2016): Targeting TRPM2 channels impairs radiation-induced cell cycle arrest and fosters cell death of T cell leukemia cells in an bcl-2-dependent manner. Oxidative Med. Cell Longev. 2016, 8026702. https://doi.org/10.1155/2016/8026702

Kondratchska K, Kondratskyy A, Yassine M, Lemonnier L, Lepage G, Morabito A, Skryma R, Prevarskaya N (2014): Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma. Biochim. Biophys. Acta 1843, 2263-2269. https://doi.org/10.1016/j.bbamcr.2014.02.012

Kumar Biswas S, Huang J, Persaud S, Basu A (2004): Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol. Cancer Ther. 3, 327-334

Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC (1993): Investigation of the subcellular distribution of the Bcl-2 oncprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53, 4701-4714

Laemmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685. https://doi.org/10.1038/227680a0

Lu H, Chen I, Shimoda LA, Park Y, Zhang C, Tran L, Zhang H, Semenza GL (2017): Chemotherapy-induced Ca2+ release stimulates breast cancer stem cell enrichment. Cell Rep. 18, 1946-1957. https://doi.org/10.1016/j.celrep.2017.02.001

Monaco G, Decrock E, Akk H, Ponsaerts R, Vervliet T, Luyten T, De Maeyer M, Missiaen L, Distelhorst CW, De Smedt H, et al. (2012): Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-XL. Cell Death Differ. 19, 295-309. https://doi.org/10.1038/cdd.2011.97

Monaghan P, Robertson D, Amos TA, Dyer MJ, Mason DY, Greaves MF (1992): Ultrastructural localization of bcl-2 protein. J. Histochem. Cytochem. 40, 1819-1825. https://doi.org/10.1177/40.12.1453000

Muscella A, Calabriso N, Vetrugno C, Fanizzi FP, De Pascali SA, Stournaras C, Lang F (2015): Impact of Na+/Ca2+ exchangers on therapy resistance of ovary carcinoma cells. Cell Physiol. Biochem. 38, 91-103. https://doi.org/10.1007/s00878-014-1439-y

Orrenius S, Zhivotovsky B, Nicotera P (2003): Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 4, 552-565. https://doi.org/10.1038/nrm1150

Park HK, Lee JE, Lim J, Kang BH (2014): Mitochondrial Hsp90s suppress calcium mediated stress signals propagating from mitochondria to the ER in cancer cells. Mol. Cancer 13, 148-159. https://doi.org/10.1186/1476-4598-13-148

Pelzl L, Hosseinzadeh Z, Alzoubi K, Al-Maghout T, Schmidt S, Stournaras C, Lang F (2015): Impact of Na+/Ca2+ exchangers on therapy resistance of ovary carcinoma cells. Cell Physiol. Biochem. 37, 1857-1868. https://doi.org/10.1007/s00878-014-1439-y

Prencipe M, Fitzpatrick P, Gorman S, Tosetto M, Klinger R, Furlong F, Harrison M, O'Connor D, Roninson IB, O'Sullivan J, McCann A (2009): Cellular senescence induced by aberrant...
MAD2 levels impacts on paclitaxel responsiveness in vitro. Br. J. Cancer **101**, 1900-1908 https://doi.org/10.1038/sj.bjc.6605419

Reed JC (1998): Bcl-2 family proteins. Oncogene **17**, 3225-3236 https://doi.org/10.1038/sj.onc.1202591

Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K, Matsuyama S, Herlitze S, Roderick HL, Bootman MD, et al. (2008): Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol. Cell **31**, 255-265 https://doi.org/10.1016/j.molcel.2008.06.014

Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt S, Liu G, Yанг W, Honisch S, Pantelakos S, Stournaras C, Honig A, Lang F (2014): Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells. Oncotarget **5**, 4799-4810 https://doi.org/10.18632/oncotarget.2035

Schmittgen TD, Livak KJ (2008): Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. **3**, 1101-1108 https://doi.org/10.1038/nprot.2008.73

Sakamura C, Hagiwara A, Fukuda K, Shimomura K, Takagi T, Kim S, Nakase Y, Miginery GA, Roderick HL, Bootman MD, Distelhorst CW (2009a): The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl. Acad. Sci. U. S. A. **106**, 14397-14402 https://doi.org/10.1073/pnas.0907551010

Rong YP, Barr P, Yee VC, Distelhorst CW (2009b) Targeting Bcl-2 based on the interaction of its BH4 domain with the 1,4,5-trisphosphate receptor. Biochim. Biophys. Acta **1793**, 971-978 https://doi.org/10.1016/j.bbamacr.2008.10.015

Schmidt S, Liu G, Liu G, Yang W, Honisch S, Pantelakos S, Stournaras C, Honig A, Lang F (2014): Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells. Oncotarget **5**, 4799-4810 https://doi.org/10.18632/oncotarget.2035

Schmittgen TD, Livak KJ (2008): Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. **3**, 1101-1108 https://doi.org/10.1038/nprot.2008.73

Schrodl K, Oelmez H, Edelmann M, Huber RM, Bergner A (2009): Altered Ca2+ homeostasis of cisplatin-treated and low level resistant non-small-cell and small-cell lung cancer cells. Cell Oncol. **31**, 301-315 http://doi.org/10.3233/CLO-2009-0472

Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012): Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. **64**, 706-721 https://doi.org/10.1111/j.1520-5058.2011.005637

Shen L, Wen N, Xia M, Zhang YU, Liu W, Xu YE, Sun L (2016): Calcium efflux from the endoplasmic reticulum regulates cisplatin-induced apoptosis in human cervical cancer HeLa cells. Oncol. Lett. **11**, 2411-2419 https://doi.org/10.3892/ol.2016.4278

Shibao K, Fiedler MJ, Nagata J, Minagawa N, Hirata K, Nakayama Y, Iwakiri Y, Nathanson MH, Yamaguchi K (2010): The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma. Cell Calcium **48**, 315-323 https://doi.org/10.1016/j.ceca.2010.09.005

Splöttstoesser F, Florea AM, Büsselberg D (2007): IP(3) receptor antagonist, 2-APB, attenuates cisplatin induced Ca2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis. Br. J. Pharmacol. **151**, 1176-1186 https://doi.org/10.1038/sj.bjp.0707335

Tang B-D, Xia X, Lv X-F, Yu B-X, Yuan J-N, Mai X-Y, Shang J-Y, Zhou J-G, Liang S-J, Pang R-P (2017): Inhibition of Orai1-mediated Ca(2+) entry enhances chemosensitivity of HepG2 hepatocarcinoma cells to5-Fluorouracil. J. Cell Mol. Med. **21**, 904-915 https://doi.org/10.1111/jcmm.13029

Towbin H, Stahelin T, Gordon J (1992): Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Biotechnology **24**, 145-149

Vervoegessem T, Yule DI, Bultynck G, Parys JB (2015): The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca²+-release channel. Biochim. Biophys. Acta **1853**, 1992-2005 https://doi.org/10.1016/j.bbamcr.2014.12.006

Volpe P, Alderson-Lang BH (1990): Regulation of inositol 1,4,5-trisphosphate-induced Ca²+ release. II. Effect of cAMP-dependent protein kinase. Am. J. Physiol. **258**, C1086-C1091 https://doi.org/10.1152/ajpcell.1990.258.6.C1086

Xu Y, Yu H, Qin H, Kang J, Yu C, Zhong J, Su J, Li H, Sun L (2012): Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. Cancer. Lett. **314**, 232-243 https://doi.org/10.1016/j.canlet.2011.09.034

Xu Y, Wang C, Li Z (2014): A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress. Mol. Clin. Oncol. **2**, 3-7 https://doi.org/10.3892/mco.2013.202

Xu Y, Li D, Zeng L, Wang C, Zhang L, Wang Y, Yu Y, Liu S, Li Z (2015a): Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells. Mol. Med. Rep. **11**, 189-195 https://doi.org/10.3892/mmr.2014.2683

Xu Y, Wang C, Su J, Xie Q, Ma L, Zeng L, Yu Y, Liu S, Li S, Li Z, Sun L (2015b): Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis. Oncol. Rep. **34**, 3051-3060 https://doi.org/10.3892/or.2015.4283

Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, Cuevas J (2011): Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J. Pharmacol. Exp. Ther. **337**, 636-643 https://doi.org/10.1124/jpet.110.172809

Received: January 13, 2019

Final version accepted: April 9, 2019

First published online: June 26, 2019